Role of Innate T Cells in Physiopathology of Systemic Sclerosis

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Innate T cells (ITC) are decreased in systemic sclerosis (SS) and an early lymphocyte innateness has been reported. In the other part, ITC are implicated on inflammatory process, including the IL-33/ST2 axis, which is also involved in ScS endotheliopathy. Data are however scarce and physiopathological mechanisms have not been assessed to date. The investigators hypothesize a global lymphocyte innateness in SSc, linked to a chronic ITC stimulation by innate signals leading to ITC exhaustion, and their potential role in endotheliopathy and fibroblast activation in SSc.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• SSc according to the 2013 ACR/EULAR 2013 criteria (or the 2001 Leroy's criteria for early SSc)

• Patients with others connective tissue disease:

‣ Systemic erythematosus lupus (SLE) according to the 2019 ACR/EULAR criteria

⁃ Primary Sjögren syndrome (pSS) according to the 2016 ACR/EULAR criteria

⁃ Rheumatoid arthritis according to the 2010 ACR/EULAR criteria

⁃ Idiopathic inflammatory myopathy (IIM) according to the 2017 ACR/EULAR criteria

• Healthy subjects from general population without known autoimmune disease or connective tissue disease

• ≥18 years-old

Locations
Other Locations
France
CHU poitiers
RECRUITING
Poitiers
Contact Information
Primary
Mickaël MARTIN, MD, PhD
mickael.martin@chu-poitiers.fr
+33549444004
Time Frame
Start Date: 2022-02-28
Estimated Completion Date: 2026-01-28
Participants
Target number of participants: 240
Treatments
Other: Blood test
Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes
Related Therapeutic Areas
Sponsors
Leads: Poitiers University Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials